This study describes the development of human myxoid liposarcoma (ML) xenografts that are morphologically and biologically very similar to the human tumor they derive from. All the xenografts that grew successfully in different passages belonged to the round cell subtype and maintained the chromosomal translocation t(12;16)(q13;p11) with the expression of the FUS-CHOP transcript that is responsible for the oncogenic transformation. The breakpoint characteristic of type I, II or III FUS-CHOP was identical to that in patients.
Introduction
Myxoid liposarcoma (ML) is the second most common subtype of liposarcoma. It accounts for one third of liposarcomas which, in turn, amount to approximately 10% of all mesenchymal malignancies.
Microscopically ML is made up of uniform round-oval primitive non-lipogenic cells and variable numbers of uni-multivacuolated lipoblasts intermixed with a well-developed plexiform capillary network and embedded in a myxoid matrix composed of hyaluronic acid. Depending on the proportion of the cellular component to the stroma and the prevalence of immature and mature cellular features ML is divided into a usual or pure subtype, and a round cell or cellular (RC) subtype. Usual ML is the most differentiated form and shows low cellularity, evidence of lipoblast differentiation and a conspicuous vascular network while the RC subtype presents the opposite extreme of the differentiation gamut, and shows high cellularity made up of primitive non-lipogenic cells, little or no intervening myxoid stroma and a capillary vascular pattern that is not easy to visualize. Diagnosis of the RC subtype requires >5% hypercellular area (1) . Irrespective of the grade of differentiation and consistent with the notion that these histologic variants belong to the same tumor category, the subtypes share the same cytogenetic abnormalities, represented by t(12;16)(p13;p11). This translocation is present in more than 90% of ML and results in fusion of the Several subtypes of chimeric transcripts with FUS/CHOP have been described, mainly involving different breakpoints in the FUS gene. Interestingly, unlike alveolar rhabdomyosarcoma and synovial sarcoma (2, 3) the prognostic significance of these variant transcripts remains to be clarified (4, 5) although the type III transcript seems correlated with a more severe outcome (6) .
Surgery, alone or with radiotherapy is the treatment of choice for localized ML. However, approximately half the patients die from metastatic disease. Chemosensitivity is limited and after failure of conventional chemotherapy (anthracyclines and ifosfamide) there is no standard of care.
Interestingly, in a recent series of advanced pretreated patients with ML (7), subsequently updated (8) , trabectedin showed both a high response rate and prolonged progression free survival (PFS).
Research. Trabectedin is a marine natural product isolated from the tunicate Ecteinascidia turbinate. It binds DNA in the minor groove at the N2 position of guanine and appears to have unique properties as far as DNA repair mechanism (9-12) and transcription regulation (13, 14) . In addition this drug seem to be able to modify the tumor microenvironment (15, 16) . See as a review (17) .
Surgical tumor specimens of ML analyzed after trabectedin showed a definite pathologic response mainly involving loss of cellular and vascular tumor components and evidence of an increase in mature lipoblasts. These findings are in keeping with the results of a recent study aimed at clarifying the mechanism of action of trabectedin on cell lines which showed a prodifferentiation effect of the drug (18) , and with one of the model proposed for sarcoma development which suggests that the fusion oncoprotein might lead to tumor initiation through a block of differentiation (19) . However, even with the highest regression score translocation gene footprints (transcript or fusion gene) persisted, indicating that the treatment was unable to eradicate the tumor completely (7).
In order to elucidate the mechanisms of selectivity of trabectedin and to optimize its use, alone or with other compounds, we set up preclinical experimental models of this human disease and conducted experiments to obtain and characterize ML xenografts from surgical tumor biopsies. We report the successful development of MLs reproducibly growing in immunodeficient mice, and mimicking the pathological and biological features of this disease, with very high sensitivity to trabectedin.
Research. 
Diagnostic assessment of human and murine xenografts -Histological characterization
The histological criteria applied to define myxoid liposarcoma histotype and its usual and round cell (RC) subtypes were as described in the WHO classification (1) . To obtain a diagnostic confirmation, we did cytogenetic analysis (FISH) and/or molecular analysis (RT-PCR) on all the tumor specimens, both human and murine xenografts.
-Cytogenetic analysis (FISH)
The characteristic translocation t(12:16) involving FUS and CHOP genes was evaluated on a selected area of sections from formalin-fixed paraffin-embedded samples, as previously reported (7) . The cases resulted negative for this chromosomal rearrangement were also tested for the alternative translocation t(12:22) involving EWS and CHOP genes (7) before ruling out the diagnosis of ML. Morphologic overlap between myxofibrosarcoma and dedifferentiated liposarcoma may in fact result in misdiagnosis.
-Molecular analysis of fusion transcripts
When frozen material was available a RT-PCR was done in order to characterize fusion transcript types. Total RNAs was extracted by the Trizol method (Life Technologies, Fredrick, MA, USA), reverse transcribed into cDNA and amplified using specific primers detecting the FUS-CHOP fusion transcript, as already described (7). All the PCR products were sequenced by an automated sequencer (3100 Genetic Analyzer, Applied Biosystem) following standard protocols and aligned with the GeneBank sequences NT_010393 (FUS gene) and NT_029419 (CHOP gene).
Research.
on July cDNA was specifically amplified for exons 2-9 of PTEN using previously published primers and conditions (20) . Exon 2 mutations were confirmed on genomic DNA using the following primers:
in the following conditions: 40 cycles at 96°C for 8 min; 95°C for 30 sec, 60°C for 30 sec, 72°C for 1 min and an extension of 72°C for 5 min.
Patients and tumors
Samples from 17 patients treated at the Fondazione IRCCS Istituto dei Tumori, Milan, whose fragments were grafted into nude mice, were revised by a pathologist. 
Establishment of tumor xenograft
Nude mice under isoflorane anesthesia were grafted bilaterally s.c. with representative human tumor fragments of about 4x4 mm derived from the samples described above. Fresh material was obtained from a surgical specimen (n=13) or from a dedicated Tru-cut (n=4) and cytogenetically/molecularly characterized ( Table 1 B) . Tumors were implanted in mice at different times of disease progression and during the period some patients were treated as detailed in the column "previous treatment".
Two to five animals were used for each specimen depending on tissue availability. The xenografts were further transplanted from mouse to mouse and a portion of each neoplastic tissue was used for histologic and cytogenetic/molecular studies. A xenograft model was considered established after the tumor tissue had been passaged three or more times in mice.
Genetic profiles
PCRs were performed using the STR multiplex kits AmpFℓSTR® IdentifilerTM PCR amplification kit (Applied Biosystem),which co-amplifies 15 STRs loci ( D8S1179, D21S11,   D7S820, CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338, D19S433, VWA, at the dose of 0.1 mg/kg, every four days for three times (q4dx3) as previously reported (22) . Each group comprised seven mice.
Drug efficacy was calculated as T/C%, where T and C are the mean tumor weights of treated and control groups, respectively.
In order to simulate the clinical situation and to evaluate the histopathological response better, ML015 xenografts were treated with trabectedin 0.1 mg/kg every seven days for six times (q7dx6).
Treatment started when tumor weight was about 900 mg (late-stage).
Results
We implanted a total of 17 sarcomas s.c. into nude mice (Table 1 A and B). In ten cases tumors grew over two passages but only in seven were continuous xenografts established. Table 2 Tumor fragments from established xenografts were frozen and subsequently retransplanted in mice, making these models potentially available for the use in other laboratories.
Histology and molecular characterization of the established xenograft models: comparison with the corresponding human tumors
The morphological features of the tumors grown in mice were very similar to those observed in the From the ML xenograft we obtained primary culture that grew very slowly and after few passages they lost the FUS-CHOP transcript and started to grow faster.
Drug sensitivity
Considering the recent evidence that ML are highly sensitive to the marine natural product trabectedin (7, 8) , we investigated the response of ML xenografts to this drug. The first experiments Table 2 (column B, right side) reports the best T/C registered for all models tested. As it can be seen the sensitivity of both type II MLs was higher compared to the type III tumors. The myxofibrosarcoma MF003 did not respond to trabectedin, whereas the dedifferentiated liposarcoma DD013 was very sensitive to the drug.
Since the xenograft ML015 was obtained from a patient who had been treated with trabectedin for six cycles, achieving a significant response, we compared the pathological and molecular response in the patient and in the correspondent xenograft after six doses. Excluding the xenografts not confirmed as ML (cases. 001, 003, 005, 008, and 013), the establishment of ML xenografts turned out to be closely related to the RC subtype. Five of the nine RC (55.5%) but none of the three usual subtypes grafted into the animals gave rise to the xenograft.
Previous chemotherapy or radiotherapy did not seem to influence the success of the implant. This may be ascribable to the retention of molecular/cytogenetic hallmarks in post-treatment human specimens even in those cases with the highest response rate (8) . Furthermore, two of the five ML xenografts harbored the type III transcript (ML004 and ML006, Table 2 ) which is less frequent than types II and I (6, 7), contains a large portion of FUS transcription factor (6) and also seems to be correlated with worse overall survival (6) even if a demonstrable prognostic effect is still lacking (5, 7).
Finally, the case with a type I transcript (ML017, Table 2 ) presented, in the human specimen and the xenograft, a mutated PTEN oncosuppressor gene, known to correlate with activation of the PI3K/AKT pathway. In addition to the more aggressive subtype, i.e. the RC one, three out of five of these cases (60%) had hallmarks related to aggressive clinical behavior, suggesting that establishment of the xenograft is likely to be related to the more biologically active tumor subtype.
Recent clinical evidence has been published that the marine natural product trabectedin is particularly effective in ML (7, 8) and studies in a immortalized ML cell line indicate that the high sensitivity of this tumor might be related to the drug's ability to act as a differentiating agent by blocking the transactivating ability of the fusion gene product (18) .
The present study indicates that ML xenografts are sensitive to trabectedin. In fact, in the ML015 case treated with the drug, the response was similar to that in previously reported series of treated patients (7), where there was a variable depletion of the tumor cells and the vascular component.
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Notably, ML015 showed the same histological response as in the patient from which the tumor was originally obtained (Figure 4 ). This strongly suggests that this preclinical model could serve as a good starting point for future pharmacological studies (12) .
Investigations are now in progress to explore whether longer treatment with trabectedin alone or combined with other compounds leads to complete eradication of the disease or, at least, reaches the high regression score seen in patient's specimens, corresponding to more than 90% loss of the tumor component. The fact that trabectedin seems very effective in ML xenografts as in clinical settings will provide suitable experimental models to explore the drug's mode of action, to investigate its potential activity alone or in combinations with other anticancer agents, and possibly to clarify differences related to the different FUS/CHOP transcript.
The main drawback of these models is the very low growth rate with an estimated doubling time of 20->70 days implying long observation times for any pharmacological experiment. This is unexpected in view of the selection in xenografts of the more aggressive subtype, which in the mouse seems to reproduce outcome characteristics more similar to the usual subtype than the RC one.
In summary the new xenografts reported offer a powerful new tool to investigate the biology of ML and to develop more selective and effective therapies, particularly for the advanced RC subtype requiring pharmacological treatment, since the localized usual myxoid subtype is mostly successfully managed by surgery with or without radiotherapy.
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